How to buy Anixa Biosciences stock | $2.79

Anixa Biosciences, Inc is a diagnostics & research business based in the US. Anixa Biosciences shares (ANIX) are listed on the NASDAQ and all prices are listed in US Dollars. Anixa Biosciences employs 7 staff and has a market cap (total outstanding shares value) of USD$67.8 million.

How to buy shares in Anixa Biosciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Anixa Biosciences. Find the stock by name or ticker symbol: ANIX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Anixa Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.79, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Anixa Biosciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Anixa Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Anixa Biosciences share price

Use our graph to track the performance of ANIX stocks over time.

Anixa Biosciences shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$2.79
52-week range	USD$1.33 - USD$4.13
50-day moving average	USD$2.5512
200-day moving average	USD$2.5191
Wall St. target price	USD$8.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.766

Buy Anixa Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Anixa Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Anixa Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anixa Biosciences price performance over time

Historical closes compared with the close of $2.79 from 2020-12-18

1 week (2021-01-14)	-36.30%
1 month (2020-12-24)	-2.11%
3 months (2020-10-22)	16.74%
6 months (2020-07-22)	-8.52%

1 year (2020-01-22)	-31.28%
2 years (2019-01-22)	-36.45%
3 years (2018-01-22)	4.65
5 years (2016-01-22)	2.57%

Anixa Biosciences financials

Gross profit TTM	USD$83,750
Return on assets TTM	-74.88%
Return on equity TTM	-147.19%
Profit margin	0%
Book value	$0.364
Market capitalisation	USD$67.8 million

TTM: trailing 12 months

Shorting Anixa Biosciences shares

There are currently 721,709 Anixa Biosciences shares held short by investors – that's known as Anixa Biosciences's "short interest". This figure is 21.3% down from 916,540 last month.

There are a few different ways that this level of interest in shorting Anixa Biosciences shares can be evaluated.

Anixa Biosciences's "short interest ratio" (SIR)

Anixa Biosciences's "short interest ratio" (SIR) is the quantity of Anixa Biosciences shares currently shorted divided by the average quantity of Anixa Biosciences shares traded daily (recently around 1.1 million). Anixa Biosciences's SIR currently stands at 0.63. In other words for every 100,000 Anixa Biosciences shares traded daily on the market, roughly 630 shares are currently held short.

However Anixa Biosciences's short interest can also be evaluated against the total number of Anixa Biosciences shares, or, against the total number of tradable Anixa Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anixa Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Anixa Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0344% of the tradable shares (for every 100,000 tradable Anixa Biosciences shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anixa Biosciences.

Find out more about how you can short Anixa Biosciences stock.

Anixa Biosciences share dividends

We're not expecting Anixa Biosciences to pay a dividend over the next 12 months.

Have Anixa Biosciences's shares ever split?

Anixa Biosciences's shares were split on 18 October 2016.

Anixa Biosciences share price volatility

Over the last 12 months, Anixa Biosciences's shares have ranged in value from as little as $1.33 up to $4.13. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anixa Biosciences's is 1.5633. This would suggest that Anixa Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Anixa Biosciences overview

Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Frequently asked questions

• What percentage of Anixa Biosciences is owned by insiders or institutions?

  Currently 5.959% of Anixa Biosciences shares are held by insiders and 7.736% by institutions.

• How many people work for Anixa Biosciences?

  Latest data suggests 7 work at Anixa Biosciences.

• When does the fiscal year end for Anixa Biosciences?

  Anixa Biosciences's fiscal year ends in October.

• Where is Anixa Biosciences based?

  Anixa Biosciences's address is: 3150 Almaden Expressway, San Jose, CA, United States, 95118

• What is Anixa Biosciences's ISIN number?

  Anixa Biosciences's international securities identification number is: US03528H1095

• What is Anixa Biosciences's CUSIP number?

  Anixa Biosciences's Committee on Uniform Securities Identification Procedures number is: 03528H109